Company and Industry Summary Company Overview - The company is engaged in the production of pharmaceuticals, specifically focusing on domestic formulations and Active Pharmaceutical Ingredients (API) [2][4]. Key Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.845 billion yuan, a year-on-year increase of 2% [4]. - The net profit attributable to shareholders was 28.82 million yuan, showing significant growth due to a low base from the previous year [4]. - The domestic formulation sales remained stable at 422 million yuan, while new products such as Jiemipule and Iodine Proamine saw sales growth exceeding three times compared to the same period last year [2][4]. API Business Performance - The API segment's shipment volume increased by 15% year-on-year to approximately 1,300 tons, with external shipments growing over 20% [2][4]. - The company expects total API shipments for the year to be between 1,800 and 2,000 tons, with several workshops having completed domestic and international GMP certifications [2][5]. Gross Margin and Cost Management - The gross margin has been continuously recovering, exceeding both the previous year's and the annual level, attributed to increased production and sales scale, as well as effective cost reduction measures [2][4]. Strategic Goals - The company aims for the formulation sales to account for about half of the entire contrast agent segment in the coming years, leveraging the iMax platform and self-operated markets [2][7]. - The goal is to fully utilize the compliant production capacity of Jiemipule by the end of next year, potentially reaching hundreds of thousands of bottles [2][5]. Market Position and Competition - The company's global market share in the API business is estimated to be around 10% to 20%, with a leading position in three main products [3][14]. - The reduction in shipment volumes from some smaller competitors presents an opportunity for the company to expand its market share [3][14]. Future Outlook - The company anticipates that the new products will contribute significantly to revenue in the fourth quarter of 2025 and into 2026, particularly following successful bids for collective procurement projects [4][5]. - The company is also focused on expanding its overseas formulation sales and has made progress in registering products in various countries [8][17]. Cost and Pricing Strategy - The overall price of raw materials has remained stable, with fluctuations of about two to three dollars this year [9]. - The company has conducted two price increases since 2022, but prices are expected to remain stable in the short term due to minimal cost fluctuations and consideration of formulation manufacturers' capacity to absorb price changes [18]. Investment and Capital Expenditure - The company has completed significant capital expenditures over the past five to six years, with all six major API varieties now industrialized and registration processes nearing completion [19]. - Future strategies include improving processes and management levels to enhance profitability while maintaining a stable dividend policy to reward investors [20].

Core Points - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary Tianyuan Pharmaceutical won the bid for the centralized procurement of traditional Chinese medicine in Guangdong [5] - The company received various drug registration certificates and approvals for its products in 2025 [5][6] - The company completed the redemption of its convertible bonds in August 2025 [6] - The company’s subsidiary Haichang Pharmaceutical obtained market access for several raw materials in South Korea and India [6] Financial Data and Indicators - The report indicates that all board members attended the meeting to review the report [2] - The company’s half-year report was disclosed on August 26, 2025, on designated platforms [8] - The company confirmed the accuracy and completeness of the information disclosed in the report [8]

Investment Rating - The report maintains a "Strong Buy" rating for the company [3]. Core Views - The company is expected to overcome operational bottlenecks and improve profitability, moving towards becoming a comprehensive supplier of contrast agents [1][7]. - The management efficiency has improved significantly under the current chairman, with revenue per employee increasing from 550,000 RMB in 2015 to 1,340,000 RMB in 2025 [7][19]. - The company is entering a phase of increased production capacity for iodine contrast agents, with capital expenditures (CAPEX) peak passed and utilization rates expected to rise [7][19]. - The domestic and international demand for contrast agents is expanding, with the company positioned as a key supplier in the iodine contrast agent market [7][27]. Financial Data and Projections - The company is projected to achieve a net profit of 0.7 billion RMB in 2025, 2.3 billion RMB in 2026, and 3.5 billion RMB in 2027, with corresponding price-to-earnings (PE) ratios of 58, 18, and 11 [8][75]. - Revenue is expected to grow from 2.196 billion RMB in 2023 to 3.516 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 15% [8][85]. - The company’s operating profit is forecasted to recover from a loss of 0.054 billion RMB in 2024 to a profit of 0.277 billion RMB in 2026 [8][85]. Market Dynamics - The global market for contrast agents is projected to grow at a compound annual growth rate (CAGR) of 6.8%, with iodine contrast agent demand expected to double in the next decade [7][31]. - The supply of iodine is constrained, with major producers unable to significantly increase output, maintaining a tight balance between supply and demand [22][27]. - The company is positioned as a leading supplier in the iodine contrast agent market, with a comprehensive product range and established customer relationships [7][34]. Production Capacity and Expansion - The company has completed the construction of over 2,400 tons of raw material capacity, with approximately 1,800 tons certified under major quality systems [7][37]. - The company plans to utilize funds from a recent capital increase to expand production capacity for non-ionic CT contrast agents and iodine compounds [37][38]. Competitive Position - The company has a significant market share in iodine contrast agents, with a focus on expanding its product offerings and enhancing its competitive edge through strategic investments [7][34]. - The domestic procurement policies are expected to benefit the company, as it has a strong cost and scale advantage in raw materials [7][57]. International Expansion - The company is leveraging its international platform, IMAX, to enhance its global presence, with sales revenue from overseas operations increasing by 60% year-on-year [72]. - The company anticipates completing EU-GMP certification for its Shanghai facility in 2025, facilitating further international market penetration [72][75].